Stay updated on Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.

Latest updates to the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page
- Check4 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing the previous Revision: v3.6.0, indicating an updated page revision. This reflects a metadata update rather than a change to the study information itself.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedNew navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment status note ('No longer looking for participants'); the Intervention/Treatment label was updated and the revision/version updated from v3.5.5 to v3.6.0.SummaryDifference0.1%

- Check25 days agoChange DetectedRevision tag updated from v3.5.4 to v3.5.5, signaling a new release of the site components.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page's revision has been updated from v3.5.3 to v3.5.4, signaling a new revision of the document. This appears to be a minor, non-user-facing update rather than a change to content or features.SummaryDifference0.0%

- Check54 days agoChange DetectedTaoyuan District, Taiwan, 333423 was updated to Taoyuan, Taiwan, 333423 in the locations list. The postal code remains 333423.SummaryDifference0.0%

- Check68 days agoChange DetectedStudy availability was updated by adding and removing certain clinical trial sites/locations, including changes to specific cities and administrative regions (e.g., in Chile, Finland, and Romania). The record also reflects an updated data-sharing detail setup around providing anonymized participant data under the study’s IPD plan.SummaryDifference0.8%

Stay in the know with updates to Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.